Skip to main content
OpenTrials
Completed

NCT Number: NCT06812416

Effectiveness of Qualia NAD+ Supplementation on NAD Levels

The current study is designed as a randomized double-blind placebo-controlled parallel trial. It aims to investigate the efficacy of Qualia NAD+ on intracellular NAD levels in blood samples (primary outcomes) and health-related quality of life (secondary outcomes) in an adult population experiencing moderate to severe joint pain between ages of 40 and 65 years.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Remote Study

Carlsbad, California, 92011, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Provide voluntary, written, informed consent to participate in the study Agree to provide a valid cell phone number and are willing to receive communications through text.

Healthy male and female participants between the ages of 40-65 years of age. Willingness to complete questionnaires, records, and diaries associated with the study.

Willing to not consume any supplements, energy drinks/shots, or other products containing any form of supplemental vitamin B3 (e.g., niacin, niacinamide, nicotinamide ribosome, NMN) starting about 2 weeks prior to the baseline NAD fingerstick test and continuing through the intervention period.

Willing to not begin taking any new supplements during the study period, and to continue taking any supplements they are currently using regularly (with the exception of vitamin B3 containing supplements).

Willing to self-administer the intracellular NAD fingerstick test kit at home for both a baseline and post-intervention blood sample, and to complete a release form that gives NHC access to the results of these tests.

Exclusion criteria

Women who are pregnant, breastfeeding, or planning to become pregnant during the trial Known food intolerances/allergy to any ingredients in the product Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer Having had a significant cardiovascular event in the past 6 months Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines On immunosuppressive therapy Individuals who were deemed incompatible with the test protocol Adults lacking capacity to consent

Treatment and study plan

Qualia NAD+

Dietary Supplement

Qualia NAD+

Rice Flour Placebo

Dietary Supplement

Rice Flour Placebo

Primary outcomes

  1. Intracellular NAD+ Levels

    Time frame: Baseline and day 28

Secondary outcomes

  1. Aging Male/Female Symptom scale

    Time frame: Baseline, day 14, and day 28

  2. RAND SF-36

    Time frame: Baseline, day 14, and day 28

Sponsors and collaborators

Lead sponsor

Qualia Life Sciences

Industry

Registry information

Official study title

Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels: A Randomized Double-Blind Parallel Trial

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Feb 6, 2025
Registry last updated
Jun 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.